- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00633165
Brostallicin Clinical Trial for Myxoid Liposarcoma (SMI-BRS-202)
A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has provided informed consent.
- Histologically confirmed myxoid liposarcoma.
- Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective.
- Patient has measurable tumor on CT, spiral CT, or MRI scan that meet RECIST criteria.
- Age ≥18 years
- Karnofsky performance status (KPS) ≥ 70% (see Appendix III).
- Life expectancy of at least 3 months.
Acceptable liver function:
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 2.5 times ULN (if liver metastases are present, then ≤ 5 × ULN is allowed).
- Acceptable renal function: For all patients serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.
Acceptable hematologic status:
- Absolute neutrophil count (ANC) ≥ 1500 cells/mm(3) (1.5 ×10(9)/L)
- Platelet count ≥ 100,000 platelet/mm(3) (100 ×10(9)/L)
- Hemoglobin ≥ 9 g/dL.
Exclusion Criteria:
Patient received any of the following within the specified time period prior to initiation of treatment in this study:
- Chemotherapy, major surgery, significant traumatic injury, or irradiation, whether conventional or investigational within 28 days
- Mitomycin-C or nitrosurea within 42 days.
- ET-743 at any time (Stage 1 only).
Patients heavily pretreated with chemotherapy and radiation, defined as follows:
- ≥ 12 cycles of an alkylating agent-containing regimen, or
- > 2 cycles carboplatin, or
- > 2 cycles mitomycin C, or
- irradiation to 25% of bone marrow-containing areas, or
- high-dose chemotherapy requiring hematopoietic stem-cell reinfusion.
- Known hypersensitivity to any study drug component.
- Uncontrolled brain metastases in the judgement of the Investigator.
Abnormal cardiac or cardiovascular function, or serious cardiac illness or medical condition in the previous 6 months including, but not confined to:
- New York Heart Association (NYHA) grade 2 or higher congestive heart failure (CHF) or who has had angioplasty or placement of coronary stents within the previous 6 months
- Myocardial infarction within the past 6 months
- High-risk uncontrolled arrhythmias
- Angina pectoris that requires antianginal medication
- Has clinically significant valvular heart disease
- Evidence of transmural infarction on ECG
- Poorly controlled hypertension (e.g., blood pressure: systolic >180 mm Hg or diastolic >100 mm Hg).
- Pregnant or lactating females. All patients (males and females) who are fertile must agree to use an effective barrier method of birth control (i.e., latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
- Not recovered from acute toxicity of all previous therapy prior to enrollment.
- History of prior malignancies within 3 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast.
- Any evidence of serious and/or unstable pre-existing medical, psychiatric, or other condition (including laboratory abnormalities) that could interfere with patient safety or obtaining informed consent.
- Any active uncontrolled infection including AIDS, hepatitis B or C.
- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow up schedule.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the overall response rate and response rate, as measured by RECIST criteria of myxoid liposarcoma with (12;16) translocation, to Brostallicin.
Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe the safety profile of Brostallicin when administered every 3 weeks in this patient population.
Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Duration of response
Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
To determine progression free survival.
Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Tumor measurements after every 2 cycles and there is no limit to the number of cycles.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jack Singer, M.D., CTI BioPharma
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMI-BRS-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myxoid Liposarcoma
-
Johnson & Johnson Pharmaceutical Research & Development...PharmaMarCompletedLiposarcoma,MyxoidFrance, United States, Germany
-
The Netherlands Cancer InstituteUnknownMyxoid Liposarcoma of Soft TissueNetherlands, United Kingdom, Norway, United States, Denmark
-
Maria Sklodowska-Curie National Research Institute...Active, not recruiting
-
Mario Negri Institute for Pharmacological ResearchFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...RecruitingLiposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round CellItaly
-
GlaxoSmithKlineCompleted
-
The Netherlands Cancer InstituteM.D. Anderson Cancer Center; Mayo Clinic; Radboud University Medical Center; Aarhus... and other collaboratorsRecruitingMyxoid LiposarcomaNetherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Daiichi Sankyo, Inc.Completed
-
Fred Hutchinson Cancer CenterIncyte CorporationActive, not recruitingRefractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditionsUnited States
-
GlaxoSmithKlineTerminatedNeoplasmsUnited States, Germany, Netherlands, Canada, Australia, Sweden
-
GlaxoSmithKlineActive, not recruitingNeoplasmsUnited States, Netherlands, Canada, United Kingdom
Clinical Trials on Brostallicin
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Gastrointestinal Stromal TumorFrance, Netherlands, Belgium, United Kingdom, Germany
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedTriple-negative Breast CancerUnited States
-
BiogenCompletedNon-Hodgkin's LymphomaUnited States
-
European Organisation for Research and Treatment...UnknownSarcoma | Small Intestine Cancer | Ovarian CancerNetherlands